Alterity Therapeutics Ltd PBT-AU:ASX

*Data is delayed | Exchange | AUD
Last | 03/28/24 AET
0.005quote price arrow up+0.001 (+25.00%)
Volume
6,050,079
52 week range
0.00 - 0.01
Loading...
  • Open0.0045
  • Day High0.005
  • Day Low0.0045
  • Prev Close0.004
  • 52 Week High0.01
  • 52 Week High Date04/06/23
  • 52 Week Low0.00
  • 52 Week Low Date11/30/23

Key Stats

  • Market Cap8.23M
  • Shares Out2,802.36M
  • 10 Day Average Volume7.84M
  • Dividend-
  • Dividend Yield-
  • Beta1.55
  • YTD % Change-28.57

KEY STATS

  • Open0.0045
  • Day High0.005
  • Day Low0.0045
  • Prev Close0.004
  • 52 Week High0.01
  • 52 Week High Date04/06/23
  • 52 Week Low0.00
  • 52 Week Low Date11/30/23
  • Market Cap8.23M
  • Shares Out2,802.36M
  • 10 Day Average Volume7.84M
  • Dividend-
  • Dividend Yield-
  • Beta1.55
  • YTD % Change-28.57

RATIOS/PROFITABILITY

  • EPS (TTM)-0.00
  • P/E (TTM)-1.00
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Alterity Therapeutics Ltd

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders...
Geoffrey Kempler
Non-Executive Chairman of the Board
David Stamler M.D.
Chief Executive Officer
Phillip Hains
Chief Financial Officer, Company Secretary
Address
L 3 460 Bourke St
Melbourne, VIC
3000
Australia